Paul Badawi Sells 24,174 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 24,174 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $2.30, for a total transaction of $55,600.20. Following the completion of the transaction, the chief executive officer now owns 6,010,580 shares in the company, valued at approximately $13,824,334. This trade represents a 0.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Paul Badawi also recently made the following trade(s):

• On Thursday, January 16th, Paul Badawi sold 24,819 shares of Sight Sciences stock. The stock was sold at an average price of $2.92, for a total transaction of $72,471.48.

Sight Sciences Stock Performance

Shares of SGHT stock opened at $2.30 on Friday. The company has a market capitalization of $118.07 million, a P/E ratio of -2.25 and a beta of 2.52. Sight Sciences, Inc. has a fifty-two week low of $2.04 and a fifty-two week high of $8.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. The stock has a 50 day moving average price of $2.67 and a two-hundred day moving average price of $3.86.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The firm had revenue of $19.07 million for the quarter, compared to the consensus estimate of $18.98 million. During the same quarter in the prior year, the company earned ($0.22) earnings per share. Analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. ProShare Advisors LLC purchased a new stake in Sight Sciences in the 4th quarter worth approximately $36,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Sight Sciences in the 4th quarter worth about $40,000. Arkadios Wealth Advisors purchased a new stake in shares of Sight Sciences in the 4th quarter worth about $47,000. WealthTrust Asset Management LLC bought a new stake in shares of Sight Sciences during the 4th quarter valued at about $48,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Sight Sciences during the fourth quarter valued at about $50,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on SGHT shares. Piper Sandler dropped their price objective on shares of Sight Sciences from $5.50 to $3.50 and set a “neutral” rating for the company in a report on Thursday, March 6th. Citigroup dropped their price target on Sight Sciences from $4.60 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a report on Thursday, March 6th. Lake Street Capital cut their target price on Sight Sciences from $3.00 to $2.50 and set a “hold” rating for the company in a research note on Thursday, March 6th. Finally, UBS Group cut their price objective on shares of Sight Sciences from $5.50 to $5.00 and set a “buy” rating for the company in a research note on Monday, January 27th. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $3.83.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.